CMBRS24006 / Falkson / NRG-BR009
Basic Study Information
Purpose:
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian
function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET
in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early-
stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative
tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25
(for pN1 patients).
Location: University of Rochester
Lead Researcher (Principal Investigator)
Lead Researcher:
Carla Falkson
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search